Source:http://linkedlifedata.com/resource/pubmed/id/17131118
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7
|
| pubmed:dateCreated |
2007-4-26
|
| pubmed:abstractText |
Cancer immunotherapy by dendritic cell (DC)/tumor cell fusion hybrids (DC/TC hybrids) has been shown to elicit potent anti-tumor effects via the induction of immune responses against multiple tumor-associated antigens. In the present study, we compared the anti-tumor effects of vaccinating Balb/c mice (H-2(d)) with CT26CL25 colon carcinoma cells that had been fused with either syngeneic DCs from Balb/c mice, allogeneic DCs from C57BL/6 mice (H-2(b)) or semiallogeneic DCs from B6D2F1 mice (H-2(b/d)). Preimmunization with either semiallogeneic or allogeneic DC/TC hybrids induced complete protection from tumor challenge, whereas mice preimmunized with syngeneic DC/TC hybrids were only partially protected (75% tumor rejection). The average number of pulmonary metastases after intravenous tumor injection decreased significantly following immunization with semiallogeneic or allogeneic DC/TC hybrids (8.3 +/- 7.9 or 16.3 +/- 3.5, mean +/- SD) relative to syngeneic DC/TC hybrids (67.8 +/- 6.3). These data demonstrate that vaccination with semiallogeneic DC/TC hybrids resulted in the greatest anti-tumor efficacy. Anti-tumor effects showed by in vivo studies were virtually accomplished by the frequency of induced CTLs specific to both gp70 and beta-galactosidase assessed by using pentameric assay. Among the fusion vaccines tested, semiallogeneic DC/TC hybrids induced the highest ratio of Th1 cytokine IFN-gamma to Th2 cytokine IL-10. In addition, allogeneic or semiallogeneic DC/TC hybrids elicited a significantly stronger NK activity than syngeneic DC/TC hybrids. These findings suggest that in clinical settings, DCs derived from a healthy donor (which are generally characterized as more semiallogeneic than allogeneic) may be more capable than autologous DCs of inducing promising anti-tumor effects in vaccinations with DC/TC hybrids.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0340-7004
|
| pubmed:author |
pubmed-author:AjikiTetsuoT,
pubmed-author:KamigakiTakashiT,
pubmed-author:KanemitsuKiyonoriK,
pubmed-author:KawasakiKentaroK,
pubmed-author:KimYongsikY,
pubmed-author:KurodaDaisukeD,
pubmed-author:KurodaYoshikazuY,
pubmed-author:NakamuraTetsuT,
pubmed-author:TakaseShiroS,
pubmed-author:YamamotoMasashiM,
pubmed-author:YasudaTakashiT
|
| pubmed:issnType |
Print
|
| pubmed:volume |
56
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1025-36
|
| pubmed:meshHeading |
pubmed-meshheading:17131118-Adenocarcinoma,
pubmed-meshheading:17131118-Animals,
pubmed-meshheading:17131118-Antigens, Neoplasm,
pubmed-meshheading:17131118-Cancer Vaccines,
pubmed-meshheading:17131118-Cell Fusion,
pubmed-meshheading:17131118-Colonic Neoplasms,
pubmed-meshheading:17131118-Cytokines,
pubmed-meshheading:17131118-Dendritic Cells,
pubmed-meshheading:17131118-Flow Cytometry,
pubmed-meshheading:17131118-Hybrid Cells,
pubmed-meshheading:17131118-Immunotherapy,
pubmed-meshheading:17131118-Mice,
pubmed-meshheading:17131118-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:17131118-Transplantation, Homologous
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma.
|
| pubmed:affiliation |
Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kobe University, Kusunoki-cho 7-5-1, Chuo-ku, Kobe 650-0017, Japan. yasudatyamane@yahoo.co.jp
|
| pubmed:publicationType |
Journal Article,
Comparative Study
|